Indication-Based Pricing - They Said It Wasn’t Possible : IC Fireside Chats - Episode 6
While many claim it’s too complex to execute—especially in oncology—this episode spotlights a bold real-world example where indication-based pricing was delivered.
Roche challenged the norm, structuring a contract that aligned price to value across multiple indications. So, what made it work?
Tune in for a five-minute breakdown of how indication-based pricing went from theory to implementation—and why data infrastructure may be the key to unlocking more deals like it.
Key Takeaways
Indication-based pricing is possible—this case shows how a major manufacturer made it work.
It starts with payer alignment—this deal succeeded by showing value by indication.
Data makes it doable—infrastructure and evidence are essential enablers.
More to come?—as pipelines expand, this approach could reshape future oncology access.
Further Reading
Dig deeper on indication-based pricing - read our article examining more case studies, and the challenges and barriers to delivering it: https://www.verpora.com/knowledge-and-resources/indication-based-pricing
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
